CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 4, 2016--
Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome
therapeutics platform company, today announced that management will host
a conference call and live audio webcast on Thursday, November 10, 2016
at 8:00 a.m. ET to discuss third quarter 2016 results and provide a
general business update.
To access the conference call, please dial 844-277-9450 (domestic) or
336-525-7139 (international) and reference the conference ID number
9944547. To join the live webcast, please visit the “Investors and
Media” section of the Seres website at www.serestherapeutics.com.
A webcast replay with corresponding slides will be available on the
Seres website beginning approximately two hours after the event and will
be archived for approximately 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc. is a leading microbiome therapeutics platform
company developing a novel class of biological drugs that are designed
to treat disease by restoring the function of a dysbiotic microbiome,
where the natural state of bacterial diversity and function is
imbalanced. Seres’ program SER-109 continues to be evaluated in a Phase
2 study in multiply recurrent C. difficile infection. Seres’
second clinical candidate, SER-287, is being evaluated in a Phase 1b
study in patients with mild-to-moderate ulcerative colitis (UC). Seres
is also developing SER-262, the first ever synthetic microbiome
therapeutic candidate, in a Phase 1b study in patients with primary CDI.
For more information, please visit www.serestherapeutics.com. Follow us
on Twitter @SeresTx.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161104005093/en/
Source: Seres Therapeutics, Inc.
IR and PR Contact:
Seres
Therapeutics
Carlo Tanzi, Ph.D., 617-203-3467
Head of Investor
Relations and Corporate Communications
Ctanzi@serestherapeutics.com
